nazartinib
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 23, 2018 (NCT03529084)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Epidermal growth factor receptorINHIBITOR
Epidermal growth factor receptor inhibitor
Epidermal growth factor receptor erbB1 inhibitor
EGF816 is an irreversible TKI that demonstrates selectivity for mutant EGFRs compared with WT EGFR and targets activating and resistance mutations with equal potency (doi: 10.1158/1538-7445.AM2014-1734).
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C(=O)Nc2nc3cccc(Cl)c3n2[C@@H]2CCCCN(C(=O)/C=C/CN(C)C)C2)ccn1- Mol. weight
- 495.03 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3787344 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03529084 | Phase 3 | Jul 23, 2018 | Novartis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 1 | 1 | 1 | 2018 |
1 organizations
Page 1 / 1